NCT06910137Available不适用
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
To provide retifanlimab, on a reactive basis, to adult patients with squamous carcinoma of the anal canal in combination with carboplatin and paclitaxel and who are considered ineligible for other therapeutic options including clinical trials.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to comprehend and willing to sign a written ICF for the study.
- •Are 18 years of age or older (or as applicable per local country requirements).
- •Histologically or cytologically verified, inoperable locally recurrent or metastatic SCAC.
- •Adequate ECOG performance status to be able to benefit from the treatment.
- •If HIV-positive, a well controlled and stable disease and receiving antiretroviral therapy (ART/HAART) and have not experienced any HIV-related opportunistic infection for at least 4 weeks prior to study enrollment.
- •Willingness to avoid pregnancy or fathering children based on the criteria below.
- •Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 120 days after the last dose of INCMGA00012 or placebo or through 180 days after the last dose of chemotherapeutic agents, whichever occurs later (or longer as appropriate based on country-specific requirements) and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.
- •Women of childbearing potential must have a negative serum pregnancy test at screening, agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty), and refrain from donating oocytes from screening through 120 days after the last dose of INCMGA00012 or placebo or through 180 days after the last dose of chemotherapeutic agents, whichever occurs later. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed. The definition of WOCBP is located in the protocol.
- •Women of nonchildbearing potential are eligible as defined in the protocol.
排除标准
- •Has received prior PD-(L)1 directed therapy.
- •Participants must have recovered from previous therapies for example including but not limited to RT and CRT.
- •Participants with laboratory values at screening defined below:
- •Hematology:
- •Platelets < 100 × 109/L.
- •Hemoglobin < 9 g/dL.
- •ANC < 1.5 x 109/L.
- •ALT ˃ 2.5 x ULN or ˃ 5 x ULN for participants with liver metastases.
- •AST ˃ 2.5 x ULN or ˃ 5 x ULN for participants with liver metastases.
- •Bilirubin ≥ 1.5 x ULN unless conjugated bilirubin ≤ ULN (conjugated bilirubin only needs to be tested if total bilirubin exceeds ULN). If there is no institutional ULN, then direct bilirubin must be < 40% of total bilirubin.
- •Calculated creatinine clearance < 50 mL/min calculated by Cockcroft-Gault equation (glomerular filtration rate can also be used in place of CrCl).
- •Coagulation:
- •INR or PT > 1.5 × ULN, for participants not receiving anticoagulant therapy.
- •aPTT > 1.5 × ULN for participants not receiving anticoagulant therapy.
- •Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg of prednisone or equivalent).
- •Evidence of interstitial lung disease or active noninfectious pneumonitis.
- •History of organ transplant, including allogeneic stem cell transplantation.
- •Known active CNS metastases and/or carcinomatous meningitis, per the protocol.
- •Known active HAV, HBV, or HCV infection, as defined by elevated transaminases with the following serology: positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or IgM, or HBsAg (in the absence of prior immunization).
- •Active infections requiring systemic therapy, or IV antibiotic use up to 7 days before Cycle 1 Day
- •Known hypersensitivity to platinum, paclitaxel, another monoclonal antibody, or any of the excipients that cannot be controlled with standard measures (eg, antihistamines, corticosteroids).
- •Participants with impaired cardiac function or clinically significant cardiac disease as assessed by the treating physician.
- •Participant is pregnant or breastfeeding.
- •Has pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE v
- •Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant.
研究者
相似试验
终止
1 期
Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal CancerAnal CancerNCT01324141National Cancer Institute (NCI)6
招募中
3 期
Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal AdenocarcinomaAdult With Intermediate Low or Mid Rectal AdenocarcinomaNCT06402864Gustave Roussy, Cancer Campus, Grand Paris212
进行中（未招募）
2 期
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal CancerColorectal Cancer Stage IIColorectal Cancer Stage IIINCT04304209Sun Yat-sen University195
招募中
2 期
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized ApproachAnal Squamous Cell CarcinomaNCT06050707University Health Network, Toronto80
已完成
1 期
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.Anus NeoplasmsHIV InfectionsNCT00000764National Institute of Allergy and Infectious Diseases (NIAID)98